Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia
2008 · Blood · 223 citations
https://doi.org/10.1182/blood-2007-08-110098
K
Kenneth I. Ataga
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
303
Papers
10.3K
Citations
50
h-index
110
i10-index
Kenneth I. Ataga is an academic researcher from University of Tennessee Health Science Center. The author has contributed to research in topics: Hemoglobinopathies and Related Disorders & Iron Metabolism and Disorders & Myeloproliferative Neoplasms: Diagnosis and Treatment. The author has an h-index of 50, co-authored 258 publications.
ORCID: 0000-0002-4501-9982Papers by this author
worksDose‐Escalation Study of ICA‐17043 in Patients with Sickle Cell Disease
2006 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 60 citations
https://doi.org/10.1592/phco.26.11.1557
Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia
2009 · Expert Opinion on Investigational Drugs · 59 citations
https://doi.org/10.1517/13543780802708011
Machine Learning to Quantitate Neutrophil NETosis
2019 · Scientific Reports · 25 citations
https://doi.org/10.1038/s41598-019-53202-5
Haemoglobin response to senicapoc in patients with sickle cell disease: a re‐analysis of the Phase III trial
2021 · British Journal of Haematology · 19 citations
https://doi.org/10.1111/bjh.17345
A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Effect of Crizanlizumab and Standard of Care (SoC) Versus Standard of Care Alone on Renal Function in Patients with Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)
2021 · Blood · 8 citations
https://doi.org/10.1182/blood-2021-149849
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat